- Home
- ITRM vs CCEL Comparison
ITRM vs CCEL Comparison
Compare ITRM & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ITRM
- CCEL
- Stock Information
- Founded
- ITRM 2015
- CCEL 1989
- Country
- ITRM Ireland
- CCEL United States
- Employees
- ITRM N/A
- CCEL N/A
- Industry
- ITRM Biotechnology: Pharmaceutical Preparations
- CCEL Managed Health Care
- Sector
- ITRM Health Care
- CCEL Health Care
- Exchange
- ITRM Nasdaq
- CCEL Nasdaq
- Market Cap
- ITRM 40.0M
- CCEL 34.8M
- IPO Year
- ITRM 2018
- CCEL 1997
- Fundamental
- Price
- ITRM $0.73
- CCEL N/A
- Analyst Decision
- ITRM Strong Buy
- CCEL Strong Buy
- Analyst Count
- ITRM 1
- CCEL 1
- Target Price
- ITRM $9.00
- CCEL $8.50
- AVG Volume (30 Days)
- ITRM 821.8K
- CCEL 17.0K
- Earning Date
- ITRM 11-13-2025
- CCEL 10-15-2025
- Dividend Yield
- ITRM N/A
- CCEL 13.22%
- EPS Growth
- ITRM N/A
- CCEL N/A
- EPS
- ITRM N/A
- CCEL N/A
- Revenue
- ITRM N/A
- CCEL $31,988,783.00
- Revenue This Year
- ITRM N/A
- CCEL $1.75
- Revenue Next Year
- ITRM $482.25
- CCEL N/A
- P/E Ratio
- ITRM N/A
- CCEL N/A
- Revenue Growth
- ITRM N/A
- CCEL 1.10
- 52 Week Low
- ITRM $0.61
- CCEL $4.09
- 52 Week High
- ITRM $3.02
- CCEL $9.43
- Technical
- Relative Strength Index (RSI)
- ITRM 50.74
- CCEL 49.28
- Support Level
- ITRM $0.66
- CCEL $4.39
- Resistance Level
- ITRM $0.83
- CCEL $4.70
- Average True Range (ATR)
- ITRM 0.05
- CCEL 0.12
- MACD
- ITRM 0.01
- CCEL -0.01
- Stochastic Oscillator
- ITRM 41.24
- CCEL 35.19
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The Public cord blood banking segment consists of cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.